Valisure is proud to announce a significant investment round led by AlleyCorp, a New York-based venture capital firm focused on healthcare innovation. This strategic funding marks a major milestone for Valisure, enabling us to accelerate research and development, grow our expert team, and further cement our role as a leader in independent pharmaceutical quality assurance.

Alongside this exciting news, we are thrilled to welcome Chip Phillips as Valisure’s new Chief Executive Officer. Chip brings decades of healthcare leadership experience and will guide the organization through critical industry challenges, including supply chain vulnerabilities, drug shortages, and quality concerns.

With this transition, Co-Founder David Light assumes the role of President, where he will focus on expanding Valisure’s mission and thought leadership through continued collaboration with government, academic, and industry partners.

We’re also pleased to announce the expansion of our executive team:

• Wolfgang Hinz – Chief Scientific Officer
• Adam Clark-Joseph – Chief Analytics Officer
• Jill Nailor, RPh – Chief Business Development Officer

This new chapter positions Valisure for impactful growth as we continue to advocate for a safer, more transparent drug supply chain.

Read the full article in Hartford Business Journal →

‍

Valisure is proud to announce a significant investment round led by AlleyCorp, a New York-based venture capital firm focused on healthcare innovation. This strategic funding marks a major milestone for Valisure, enabling us to accelerate research and development, grow our expert team, and further cement our role as a leader in independent pharmaceutical quality assurance.

Alongside this exciting news, we are thrilled to welcome Chip Phillips as Valisure’s new Chief Executive Officer. Chip brings decades of healthcare leadership experience and will guide the organization through critical industry challenges, including supply chain vulnerabilities, drug shortages, and quality concerns.

With this transition, Co-Founder David Light assumes the role of President, where he will focus on expanding Valisure’s mission and thought leadership through continued collaboration with government, academic, and industry partners.

We’re also pleased to announce the expansion of our executive team:

• Wolfgang Hinz – Chief Scientific Officer
• Adam Clark-Joseph – Chief Analytics Officer
• Jill Nailor, RPh – Chief Business Development Officer

This new chapter positions Valisure for impactful growth as we continue to advocate for a safer, more transparent drug supply chain.

Read the full article in Hartford Business Journal →

‍